{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:15:26Z","timestamp":1761513326440},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2013,7,26]],"date-time":"2013-07-26T00:00:00Z","timestamp":1374796800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0070139","type":"journal-article","created":{"date-parts":[[2013,7,27]],"date-time":"2013-07-27T01:12:22Z","timestamp":1374887542000},"page":"e70139","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["E- and P-Selectins Are Essential for Repopulation of Chronic Myelogenous and Chronic Eosinophilic Leukemias in a Scid Mouse Xenograft Model"],"prefix":"10.1371","volume":"8","author":[{"given":"Daniel","family":"Wicklein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Labitzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,7,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"E Shtivelman","year":"1985","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","article-title":"Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"JM Goldman","year":"2001","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"JV Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1535-6108(02)00025-9","article-title":"Perspectives on the development of a molecularly targeted agent","volume":"1","author":"BJ Druker","year":"2002","journal-title":"Cancer Cell"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"SG O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"BJ Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"FX Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"J Cortes","year":"2004","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"M Copland","year":"2006","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2141.2008.07197.x","article-title":"Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease","volume":"142","author":"P Valent","year":"2008","journal-title":"Br J Haematol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"X Jiang","year":"2007","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.molmed.2007.09.003","article-title":"Right on target: eradicating leukemic stem cells","volume":"13","author":"DS Krause","year":"2007","journal-title":"Trends Mol Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11899-012-0121-6","article-title":"Chronic myeloid leukemia stem cell biology","volume":"7","author":"LA Crews","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2012.00086","article-title":"Targeting myelogenous leukemia stem cells: role of the circulation","volume":"2","author":"J Liesveld","year":"2012","journal-title":"Front Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.leu.2403313","article-title":"Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias","volume":"18","author":"P Vandenberghe","year":"2004","journal-title":"Leukemia"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-007-0403-6","article-title":"The diagnosis of BCR\/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers","volume":"87","author":"T Haferlach","year":"2008","journal-title":"Ann Hematol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.beha.2005.07.013","article-title":"Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy","volume":"19","author":"J Gotlib","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.blre.2009.01.001","article-title":"Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders","volume":"23","author":"P Valent","year":"2009","journal-title":"Blood Rev"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bbrc.2007.12.063","article-title":"Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha","volume":"366","author":"K Ishihara","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaci.2010.03.042","article-title":"Refining the definition of hypereosinophilic syndrome","volume":"126","author":"HU Simon","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2008.287","article-title":"Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias","volume":"22","author":"J Gotlib","year":"2008","journal-title":"Leukemia"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"J Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","article-title":"Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study","volume":"143","author":"G Metzgeroth","year":"2008","journal-title":"Br J Haematol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/sj.bjc.6605492","article-title":"E\u2212\/P-selectins and colon carcinoma metastasis: first in vivo evidence for their crucial role in a clinically relevant model of spontaneous metastasis formation in the lung","volume":"102","author":"S K\u00f6hler","year":"2009","journal-title":"Br J Cancer"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canlet.2012.02.019","article-title":"Selectin-deficiency reduces the number of spontaneous metastases in a xenograft model of human breast cancer","volume":"321","author":"K St\u00fcbke","year":"2012","journal-title":"Cancer Lett"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/nm.2969","article-title":"Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance","volume":"18","author":"IG Winkler","year":"2012","journal-title":"Nat Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nri2156","article-title":"Getting to the site of inflammation: the leukocyte adhesion cascade updated","volume":"7","author":"K Ley","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e30567","DOI":"10.1371\/journal.pone.0030567","article-title":"Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model","volume":"7","author":"D Wicklein","year":"2012","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/1471-2407-10-295","article-title":"Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung","volume":"10","author":"T Kalinina","year":"2010","journal-title":"BMC Cancer"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","article-title":"Guidelines for the welfare and use of animals in cancer research","volume":"102","author":"P Workman","year":"2010","journal-title":"Br J Cancer"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00418-011-0804-4","article-title":"Adhesion of small cell lung cancer cells to E- and P-selectin under physiological flow conditions: implications for metastasis formation","volume":"135","author":"U Richter","year":"2011","journal-title":"Histochem Cell Biol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/sj.bjc.6603594","article-title":"Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice","volume":"96","author":"A Thies","year":"2007","journal-title":"Br J Cancer"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.acthis.2009.05.004","article-title":"Comparison of two techniques for the screening of human tumor cells in mouse blood: quantitative real-time polymerase chain reaction (qRT-PCR) versus laser scanning cytometry (LSC)","volume":"112","author":"N Nehmann","year":"2009","journal-title":"Acta Histochem"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Gebauer F, Wicklein D, Stubke K, Nehmann N, Schmidt A, <etal>et al<\/etal>.. (2012) Selectin binding is essential for peritoneal carcinomatosis in a xenograft model of human pancreatic adenocarcinoma in pfp\u2212\/rag2\u2013 mice. Gut.","DOI":"10.1136\/gutjnl-2011-300629"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nature09262","article-title":"Mesenchymal and haematopoietic stem cells form a unique bone marrow niche","volume":"466","author":"S Mendez-Ferrer","year":"2010","journal-title":"Nature"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood-2009-01-202606","article-title":"The leukemic stem cell niche: current concepts and therapeutic opportunities","volume":"114","author":"SW Lane","year":"2009","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2005.05.026","article-title":"SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells","volume":"121","author":"MJ Kiel","year":"2005","journal-title":"Cell"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1172\/JCI119142","article-title":"Selectin ligands: will the real ones please stand up?","volume":"99","author":"A Varki","year":"1997","journal-title":"J Clin Invest"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jim.2012.07.003","article-title":"HECA-452 is a non-function blocking antibody for isolated sialyl Lewis x adhesion to endothelial expressed E-selectin under flow conditions","volume":"384","author":"CM Kummitha","year":"2012","journal-title":"J Immunol Methods"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1126\/science.1701274","article-title":"ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex","volume":"250","author":"ML Phillips","year":"1990","journal-title":"Science"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.88.14.6224","article-title":"CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same carbohydrate ligand, sialyl-Lewis x","volume":"88","author":"MJ Polley","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"6743","DOI":"10.1182\/blood-2011-07-343566","article-title":"Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow","volume":"118","author":"A Zarbock","year":"2011","journal-title":"Blood"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2007.03.011","article-title":"Complete identification of E-selectin ligands on neutrophils reveals distinct functions of PSGL-1, ESL-1, and CD44","volume":"26","author":"A Hidalgo","year":"2007","journal-title":"Immunity"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2174\/156800911793743655","article-title":"Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept","volume":"11","author":"P Valent","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.drup.2009.06.001","article-title":"Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches","volume":"12","author":"M Konopleva","year":"2009","journal-title":"Drug Resist Updat"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.molonc.2010.06.001","article-title":"Targeting leukemic stem cells by breaking their dormancy","volume":"4","author":"MA Essers","year":"2010","journal-title":"Mol Oncol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrc3368","article-title":"Cancer stem cell definitions and terminology: the devil is in the details","volume":"12","author":"P Valent","year":"2012","journal-title":"Nat Rev Cancer"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0070139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T15:43:35Z","timestamp":1563551015000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0070139"}},"subtitle":[],"editor":[{"given":"Ken","family":"Mills","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,7,26]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2013,7,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0070139","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,26]]}}}